[go: up one dir, main page]

PE20081441A1 - Subtipo de amidas selectivas de diazabicicloalcanos - Google Patents

Subtipo de amidas selectivas de diazabicicloalcanos

Info

Publication number
PE20081441A1
PE20081441A1 PE2007001487A PE2007001487A PE20081441A1 PE 20081441 A1 PE20081441 A1 PE 20081441A1 PE 2007001487 A PE2007001487 A PE 2007001487A PE 2007001487 A PE2007001487 A PE 2007001487A PE 20081441 A1 PE20081441 A1 PE 20081441A1
Authority
PE
Peru
Prior art keywords
subtype
ilcarbonyl
octane
diazabicicloalkanes
amidas
Prior art date
Application number
PE2007001487A
Other languages
English (en)
Inventor
Lan Miao
V Srinivasa Murthy
Regina Whitaker
Scott R Breining
Matt S Melvin
Anatoly A Mazurov
Yun-De Xiao
Philips S Hammond
Craig H Miller
Srinivisa Rao Akireddy
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of PE20081441A1 publication Critical patent/PE20081441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 0-1; Cy ES 2-FURANILO, 3-FURANILO, 2-OXAZOLILO, 2-TIAZOLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(FURAN-2-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; N-(3-METILFURAN-2-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; N-(1,2,4-TIADIAZOL-5-ILCARBONIL)-3,7-DIAZABICICLO[3.3.0]OCTANO; ENTRE OTROS. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DE RECEPTORES NICOTINICOS NEURONALES DE ACETILCOLINA DEL SUBTIPO ALFA4BETA2 UTILES EN EL TRATAMIENTO DE DEMENCIA SENIL, DISLEXIA, ESQUIZOFRENIA, DEMENCIA VASCULAR, ENTRE OTROS
PE2007001487A 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos PE20081441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85607906P 2006-11-02 2006-11-02

Publications (1)

Publication Number Publication Date
PE20081441A1 true PE20081441A1 (es) 2008-10-30

Family

ID=39233054

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001487A PE20081441A1 (es) 2006-11-02 2007-10-31 Subtipo de amidas selectivas de diazabicicloalcanos
PE2011000136A PE20110671A1 (es) 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2011000136A PE20110671A1 (es) 2006-11-02 2007-10-31 Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina

Country Status (32)

Country Link
US (6) US8114889B2 (es)
EP (2) EP2094703B1 (es)
JP (2) JP5539723B2 (es)
KR (2) KR101415705B1 (es)
CN (4) CN101528745B (es)
AR (2) AR063451A1 (es)
AT (2) ATE509022T1 (es)
AU (2) AU2007317433B2 (es)
BR (2) BRPI0717930A2 (es)
CA (1) CA2663925C (es)
CL (1) CL2007003155A1 (es)
CO (1) CO6180435A2 (es)
CY (1) CY1112374T1 (es)
DK (1) DK2094703T3 (es)
ES (2) ES2395212T3 (es)
HR (1) HRP20110570T1 (es)
IL (2) IL197618A (es)
MX (1) MX2009004801A (es)
MY (2) MY145602A (es)
NO (1) NO20091251L (es)
NZ (2) NZ575557A (es)
PE (2) PE20081441A1 (es)
PL (1) PL2094703T3 (es)
PT (1) PT2094703E (es)
RS (1) RS51834B (es)
RU (2) RU2517693C2 (es)
SA (1) SA07280584B1 (es)
SI (1) SI2094703T1 (es)
TW (3) TWI454262B (es)
UA (2) UA106718C2 (es)
UY (1) UY30686A1 (es)
WO (1) WO2008057938A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
JP2011513421A (ja) * 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2009113950A1 (en) * 2008-03-10 2009-09-17 Astrazeneca Ab Therapeutic combinations of (a) an antipsychotic and (b) an alpha-4/beta-2 (a4b2)-neuronal nicotinic receptor agonist
JP5508400B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2009147189A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
WO2010028011A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
WO2010028033A1 (en) * 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclooctanes and uses thereof
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
WO2010125082A1 (en) 2009-04-30 2010-11-04 Glaxo Group Limited Oxazole substituted indazoles as pi3-kinase inhibitors
RU2417082C2 (ru) * 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
DK2513085T3 (en) 2009-11-18 2016-12-05 Suven Life Sciences Ltd Alfa4beta2 bicyclic compounds as nicotinic acetylcholine receptor ligands
MX2012006909A (es) 2009-12-29 2012-07-10 Suven Life Sciences Ltd LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA.
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
AU2015238537B2 (en) 2014-03-26 2019-08-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
SG10202011669PA (en) 2014-10-20 2020-12-30 Oyster Point Pharma Inc Methods of treating ocular conditions
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
KR20180054635A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서 이환형 화합물
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
CN115124538A (zh) 2015-09-24 2022-09-30 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
RU2725138C2 (ru) 2015-09-24 2020-06-30 Ф. Хоффманн-Ля Рош Аг Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca)
MX385698B (es) 2016-04-07 2025-03-18 Oyster Point Pharma Inc Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
JP7157755B2 (ja) 2017-03-16 2022-10-20 エフ．ホフマン－ラ ロシュ アーゲー 二重ａｔｘ／ｃａ阻害剤として有用な複素環式化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
AR111295A1 (es) * 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
RS67259B1 (sr) 2019-09-19 2025-10-31 Novo Nordisk Healthcare Ag Kompozicije koje aktiviraju piruvat kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5468858A (en) 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
US5457121A (en) 1994-09-02 1995-10-10 Eli Lilly And Company Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
ATE289607T1 (de) * 1999-12-14 2005-03-15 Neurosearch As Neue heteroaryl-diazabizykloalkane
US6809105B2 (en) * 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
DE60215172T2 (de) 2001-07-06 2007-08-30 Neurosearch A/S Neue verbindungen, deren herstellung und verwendung
SE0202430D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202465D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
NZ540998A (en) * 2003-02-27 2008-06-30 Neurosearch As Novel diazabicyclic aryl derivatives
CN1317280C (zh) * 2003-02-27 2007-05-23 神经研究公司 新的二氮杂双环芳基衍生物
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7365193B2 (en) * 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
PL1761542T3 (pl) * 2004-06-09 2008-06-30 Hoffmann La Roche Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
CA2574307A1 (en) 2004-07-22 2006-02-02 Cumbre Pharmaceuticals Inc. Rifamycin derivatives for treating microbial infections
MX2007013986A (es) 2005-05-13 2008-02-22 Lexicon Pharmaceuticals Inc Compuestos multiciclicos y metodos para su uso.
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺

Also Published As

Publication number Publication date
AR079840A2 (es) 2012-02-22
JP5539723B2 (ja) 2014-07-02
MY145602A (en) 2012-03-15
AU2007317433A1 (en) 2008-05-15
US20160039833A1 (en) 2016-02-11
CN102020646B (zh) 2013-11-13
AU2010219323A1 (en) 2010-09-30
UA98944C2 (ru) 2012-07-10
RU2009138600A (ru) 2011-04-27
IL209026A (en) 2014-03-31
ATE509022T1 (de) 2011-05-15
US20130005789A1 (en) 2013-01-03
CN102838605B (zh) 2017-04-26
MX2009004801A (es) 2009-07-31
KR20090074051A (ko) 2009-07-03
EP2094703B1 (en) 2011-05-11
ES2395212T3 (es) 2013-02-11
TWI405763B (zh) 2013-08-21
SI2094703T1 (sl) 2011-07-29
IL209026A0 (en) 2011-01-31
RU2448969C2 (ru) 2012-04-27
PT2094703E (pt) 2011-07-22
DK2094703T3 (da) 2011-08-29
US20100081683A1 (en) 2010-04-01
EP2284171A1 (en) 2011-02-16
CO6180435A2 (es) 2010-07-19
US20150080576A1 (en) 2015-03-19
CN102838605A (zh) 2012-12-26
CL2007003155A1 (es) 2008-05-16
EP2094703A1 (en) 2009-09-02
UA106718C2 (uk) 2014-10-10
KR101415705B1 (ko) 2014-07-04
CN102942569A (zh) 2013-02-27
TW200826935A (en) 2008-07-01
TWI404532B (zh) 2013-08-11
MY156730A (en) 2016-03-15
CA2663925C (en) 2015-04-21
RU2517693C2 (ru) 2014-05-27
TW201305176A (zh) 2013-02-01
HK1149751A1 (en) 2011-10-14
PE20110671A1 (es) 2011-10-20
TW201114424A (en) 2011-05-01
ES2395157T3 (es) 2013-02-08
PL2094703T3 (pl) 2011-10-31
US20120289572A1 (en) 2012-11-15
HK1133260A1 (en) 2010-03-19
AU2007317433B2 (en) 2012-05-10
CA2663925A1 (en) 2008-05-15
ATE545646T1 (de) 2012-03-15
SA07280584B1 (ar) 2010-11-02
NZ575557A (en) 2011-01-28
EP2284171B1 (en) 2012-02-15
AU2010219323B2 (en) 2012-05-03
CN101528745A (zh) 2009-09-09
KR20100124356A (ko) 2010-11-26
AR063451A1 (es) 2009-01-28
JP2010509230A (ja) 2010-03-25
JP5739398B2 (ja) 2015-06-24
US8859609B2 (en) 2014-10-14
IL197618A (en) 2013-09-30
HRP20110570T1 (hr) 2011-09-30
CN101528745B (zh) 2011-09-14
US8921410B2 (en) 2014-12-30
IL197618A0 (en) 2009-12-24
RU2009120674A (ru) 2010-12-10
NO20091251L (no) 2009-05-28
US9580434B2 (en) 2017-02-28
TWI454262B (zh) 2014-10-01
CN102942569B (zh) 2015-10-28
RS51834B (sr) 2012-02-29
BRPI0717930A2 (pt) 2011-05-10
BRPI0722387A2 (pt) 2023-02-23
US8114889B2 (en) 2012-02-14
CN102020646A (zh) 2011-04-20
US20100173932A1 (en) 2010-07-08
CY1112374T1 (el) 2015-12-09
JP2013056919A (ja) 2013-03-28
WO2008057938A1 (en) 2008-05-15
US8268860B2 (en) 2012-09-18
UY30686A1 (es) 2009-08-03
NZ587847A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
PE20081441A1 (es) Subtipo de amidas selectivas de diazabicicloalcanos
WO2008062905A3 (en) Heteromonocyclic compound and use thereof
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
NI200700156A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurológicos
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
NZ588121A (en) Novel estrogen receptor ligands
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
NO20082096L (no) Azaindol-2-karboksamidderivativer
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
ATE528306T1 (de) Benzoxazepin-verbindungen, ihre herstellung und verwendung
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
PE20061295A1 (es) Derivados de acetileno
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
NZ597866A (en) Therapeutic lactams
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
MA32375B1 (fr) Derives de 5-hydroxymethyl-oxazolidine-2-one pour le traitement de maladies intestinales bacteriennes
EA200970404A1 (ru) Соединения, проявляющие активность в отношении св
NO20072060L (no) 2-acylaminotiazolderivater
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
CO6280402A2 (es) Derivados de pirazol como inhibidores de 5-10

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed